News from the European Society of Cardiology congress in Vienna, August 30 to September 3, 2003.

[1]  G. Tenderich,et al.  Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation. , 2004, European heart journal.

[2]  K. Kuck,et al.  „Homing effect“ directs mesenchymal stem cells to develop a myogenic phenotype , 2004 .

[3]  K. Kuck,et al.  Via induction of differentiation from human bone marrow derived mesenchymal stem cells to adult cardiomyocytes , 2004 .

[4]  P. Merlet,et al.  Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model. , 2003, Blood.

[5]  R. Schwinger,et al.  Ser16-, but not Thr17-phosphorylation of phospholamban influences frequency-dependent force generation in human myocardium , 2003, Pflügers Archiv.

[6]  W. Weaver,et al.  Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial , 2003, The Lancet.

[7]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[8]  K. Fox,et al.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) , 2003, The Lancet.

[9]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[10]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[11]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[12]  P. Poole‐Wilson,et al.  Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial , 2003, The Lancet.

[13]  S. Haunsø,et al.  318 Activation of E2F transcription factors in cardiac hypertrophy , 2003 .

[14]  A. Leite-Moreira,et al.  210 Differential effects of pressure vs. volume acute cardiac overload on SERCA2a and phospholamban gene expression , 2003 .

[15]  Michael R Rosen,et al.  Expression and Function of a Biological Pacemaker in Canine Heart , 2003, Circulation.

[16]  L. Hovemadsen.  734 Increased number of Ca2+ sparks and waves in human atrial myocytes from patients with atrial enlargement , 2003 .

[17]  R. Hassink.  3659 Induction of human embryonic stem cell-differentiation into cardiomyocytes , 2003 .

[18]  R. Hinrichsen.  148 Activation of E2F transcription factors in cardiac hypertrophy , 2003 .

[19]  F. See.  P2888 p38 mitogen-activated protein kinase-mediated fibrosis following myocardial infarction is regulated by connective tissue growth factor , 2003 .

[20]  M. Vantler.  P3158 The antiapoptotic effect of platelet-derived growth factor-AA is mediated by P13-kinase/Akt and negatively regulated by Src-kinases , 2003 .

[21]  S. Davani.  P1198 Transplanted mesenchymal progenitor cells differentiate to an endothelial phenotype and improve heart function in infarcted rat myocardium , 2003 .

[22]  N. Vanroyen.  3559 CD44 is signalling is required for a normal arteriogenic response: effects on leukocyte trafficking and expression of basic fibroblast growth factor and platelet-derived growth factor , 2003 .

[23]  J. Schrickel.  1294 Atrial fibrillation and ventricular tachycardia in Annexin A7-deficient mice , 2003 .

[24]  K. Brixius.  161 Ser16-, but not Thr17-phosphorylation of phospholamban influences frequency-dependent force generation in human myocardium , 2003 .

[25]  K. Jaquet.  321 Via induction of differentiation from human bone marrow derived mesenchymal stem cells to adult cardiomyocytes , 2003 .

[26]  G. Antoons.  660 Altered phosphorylation status of phopholamban, PLB, and its contribution to the negative 6Ca2+9i-frequency relationship in the MLP-I-mouse with heart failure , 2003 .

[27]  A. Schmidt.  3563 Induction of the protein-kinase B cell-survival pathway by moderate exercise training in the heart , 2003 .

[28]  P. Schott.  P411 Proteom analysis of rat myocardium: influence of neurohumoral factors and mechanical load , 2003 .

[29]  A. Technau.  P1199 Bone marrow derived human mesenchymal stem cells have the potential for myogenic differentiation both in vivo and in vitro , 2003 .

[30]  K. Jaquet.  320 Homing effect directs mesenchymal stem cells to develop a myogenic phenotype , 2003 .

[31]  F. Stillitano.  733 A molecular basis for HCN channel over-expression , 2003 .

[32]  E. Hochl.  3662 Cellular repopulation of myocardial infarction in patients with sex-mismatched heart transplantation , 2003 .

[33]  S. Schirmer.  739 Leptin, a new target for stimulation of collateral artery growth , 2003 .

[34]  L. Nanni.  1310 Expression profiling of human hypertrophic cardiomyopathy progressed to dilated cardiomyopathy by DNA microarray analysis: Insight into the pathogenesis of phenotypes , 2003 .

[35]  F. Norol.  1982 Influence of mobilized stem cells on myocardial infarct repair in a non-human primate model of acute myocardial infarction , 2003 .

[36]  R. Rosso.  1981 Increased proportion of circulating progenitor cells in the early phase of acute myocardial infarction , 2003 .

[37]  A. Rastan.  3663 Electrophysiological and coupling characteristics of bone marrow-derived mononuclear cells in coculture , 2003 .

[38]  R. Hassink.  144 Blocking p193 and p53 pro-apoptotic pathways has positive effects on cardiac morphology and function after myocardial infarction , 2003 .

[39]  L. Cheng.  P1194 Autologous marrow stromal cell transplantation improves cardiac function after myocardial infartion in rats , 2003 .

[40]  F. See.  265 p38 mitogen-activated protein kinase inhibition prevents early adverse ventricular remodelling in the immediate post-myocardial infarction setting , 2003 .

[41]  C. Napoli,et al.  Statin effects beyond lipid lowering--are they clinically relevant? , 2003, European heart journal.

[42]  O. Hess,et al.  Novel management strategy for patients with suspected pulmonary embolism. , 2003, European heart journal.

[43]  Panos Vardas,et al.  Update of the guidelines on sudden cardiac death of the European Society of Cardiology. , 2003, European heart journal.

[44]  A. Moss.  MADIT-II and its implications. , 2003, European heart journal.